Opinion
Video
Author(s):
Stacey Cohen, MD, discusses the rationale and study design of the phase 2/3 CIRCULATE-NORTH AMERICA study evaluating adjuvant chemotherapy selection based on MRD, and the panel discusses barriers to enrollment.
FDA Grants Accelerated Approval to Encorafenib Plus Cetuximab and Chemo for BRAF V600E+ Metastatic Colorectal Cancer
Zanubrutinib Leads the Way for Advancements in CLL Management: With Mazyar Shadman, MD, MPH
BTK Inhibitor–Based Combinations Represent the Future of MCL Management
Delve into Recent NCCN Guideline Updates for Hepatobiliary and CRC Management: With Alan P. Venook, MD
The Microbiome and Colon Cancer: Dietary Influence on Incidence, Morbidity, and Mortality
CHMP Recommends Approval of Nivolumab/Ipilimumab in MSI-H/dMMR mCRC
Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC
Lenvatinib Shows Efficacy in Advanced HCC Post-Progression on Atezolizumab/Bevacizumab
Sacituzumab Govitecan Does Not Significantly Improve OS in Pretreated Urothelial Carcinoma
Active Monitoring Is Noninferior to Guideline Concordant Care in Low-Risk DCIS